Polarean Imaging Share Discussion Threads

[pirates4] 13/5/2024 09:59

All this regret before its too late. Its hiding up.soon.

[moontheloon] 13/5/2024 07:38

We expect additional orders to come in this year that will result in additional 2024 revenue. We are very excited to see that our commercial growth strategy is yielding tangible results."Cvj has always been assured and confident he has plenty irons in the fire for sales.  

[moontheloon] 13/5/2024 07:34

Finance in place ready to access halfwit. No panic two big deals in 5 day period. 2024 revenue targets already hit in May. Budgets finally at the point of traction with built in red tape and admin as the deals start to flow. No one pays a million dollars to a company without a solid financial plan to provide. This is one of the best medtech stories of this generation finally unfurling its potential. Won't be single figures for long don't miss out.

[halfpenny] 12/5/2024 23:29

Pirates and Bones,

Much appreciate your updates so looks like a high risk until Capital Raise is completed and Deals provide better returns.

Expect a rapid pullback this week!!!

[pirates4] 12/5/2024 19:10

Good tech good reviews cheap aswell

[purchaseatthetop] 12/5/2024 18:09

So, that will be next week then! Fully agree. Amazing tech but medical devices breaking the US market is along hard road.

[chester9] 12/5/2024 17:27

Good cover by Paul Scot on his podcast. He agrees great tech but recommends holding back until cash is sorted.

[moontheloon] 12/5/2024 15:24

That's company again! https://www.linkedin.com/posts/the-university-of-iowa-institute-for-clinical-and-translational-science_advancedimaging-prolongedsymptoms-medicalresearch-activity-7191813736058249217-q3IT?utm_source=share&utm_medium=member_android

[pirates4] 12/5/2024 12:06

Bones698, it might not go that low. Its been going up so far. Just don't know what will happen here tomorrow.

[moontheloon] 12/5/2024 08:04

We maybe getting tipped again soon. British bulls are now on buy

[bones698] 11/5/2024 22:46

Halfpenny the simple answer is yes they need to raise funds very very soon in the worst market for a long time. Probably at between 1-2p looking how others have fared doing similar in this market.

They won't be anywhere near break even probnaly for years to come either which means the possibility of even more csah raises in the future. Progress has been at a snails pace on commercialisation and this fund raise will wipe out most holders imo

Wethwr you think it's worth a gamble after that is each person's own decision but for me it's not looking good at all.

Anothe concern is the value of the system which means deals and installs are quite low in value like 80k in most cases. That will take a large number of installs to get to break even.

[pirates4] 11/5/2024 22:15

This was at 64p in 2022 with FDA approval.

[pirates4] 11/5/2024 21:02

https://www.auntminnie.com/clinical-news/mri/article/15632641/fda-approves-polareans-xenoviewThe lung image is so clear than traditional mri scan.

[pirates4] 11/5/2024 20:58

Have a long read on 129Xe gashttps://www.pulmonologyadvisor.com/home/general-pulmonology/129xe-mri-offers-detailed-view-of-pulmonary-function-and-huge-clinical-potential/

[pirates4] 11/5/2024 19:19

Polarean is also yet another business whose product offering has been given a boost due to COVID.Following FDA approval Polarean is able to market its system to the US clinical market. As the Group has already been preparing the ground for a commercial launch, sales could conceivably start to be made in quick time.The investment by Braco Group, a big player in diagnostic imaging agents generating revenues of over $1.5 billion, offers further credibility to Polarean's offering. Braco previously acquired Blue Earth Diagnostics, a molecular imaging diagnostics company, for US$450m. Jonathan Allis, current Non-Executive Chairman of Polarean, was the founding CEO of Blue Earth.

[pirates4] 11/5/2024 18:29

Polx is funded until October, funding received from institutions as well as government. Its in their report. The government has its slice of it, too. Its FDA approved a huge plus trials all ready done by clinicians world wide. Worldwide interest very soon.

[halfpenny] 11/5/2024 15:49

Do they need to Raise Capital hence pullback....??

[goldbutler] 11/5/2024 10:50

Commercial traction news update yesterday with a very impressive top 100 hospital

UAB Hospital again named to 100 Great Hospitals list
by Alicia Rohan
May 27, 2020 Print Email
Nurse wearing blue safety gloves is tending to a premature baby in a neonatal incubator in the Regional Neonatal Intensive Care Unit (NICU), 2019.For the eighth year in a row, University of Alabama at Birmingham Hospital has been listed on Becker’s Hospital Review’s 2020 list of 100 Great Hospitals in America. UAB has earned this distinction every year since 2013



Dr VonJacko said We expect additional orders to come in this year that will result in additional 2024 revenue.

Mr Dusek said
We are continuing to have productive meetings with our other high-priority centres, as they work through the necessary steps of the value assessment and procurement process. These centres are becoming increasingly aware of our technology's clinical, scientific, and economic value in lung ventilation, as well as research into gas exchange and cardiopulmonary for future applications, where we recently strengthened our patent portfolio."

[john henry] 11/5/2024 09:02

Given yesterdays volume Amati will be out imho.

The huge stock overhang thats been there for months, is no more.

[john henry] 11/5/2024 08:51

It may take 20 plus years, but this tech could eventually be in every MRI machine.

This acorn could certainly grow into a mighty Oak

Patience and time and U could hold a Unicorn

[ohisay] 11/5/2024 08:36

The bull case FWIW.

Stifel reiterated its #Buy rating & its target price of :43p (current price: 4p) #POLX

We see encouraging evidence of building commercial interest in #Xenoview....we believe delivery on commercial targets for 2024/25 has the potential to significantly re-rate the shares from current lows



I retain a small position as a punt though one should have no illusions here..!

[bones698] 11/5/2024 07:04

It's the beginning of them needing ga lot more money and that will start by wiping out most holders. Look around the market it's littered with companies that have had to raise at massive discounts some as much as 80%. And that's after they have already fallen huge amounts.

Polx need to raise we know that I don't understand peipek seem to be in denial what's going to happen here.
Mark these words, you will all be sat on bigger losses very soon when the placing comes. Don't say you weren't warned and start whining

[pirates4] 10/5/2024 21:13

??FDA clears Polarean's lung disease diagnostic XenoviewNews?US medtech company Polarean Imaging has secured FDA approval for Xenoview, a drug device combination used alongside magnetic resonance imaging (MRI) to measure how well the lungs are functioning.The diagnostic consists of a new hyperpolarised contrast agent based on xenon 129 gas, with a chest coil device used to enhance the MRI signal within the lungs and image processing software in order to provide a visual representation of lung ventilation.It has been approved for evaluation of lung ventilation in adults and paediatric patients aged 12 years and older and, according to Polarean, is the first and only inhaled MRI hyperpolarised contrast agent to reach the market. It provides an alternative to other lung ventilation assessment technologies that use potentially harmful ionising radiation, like computed tomograph (CT) scanning.MRI has only recently emerged as an option for lung ventilation testing, aided by technological advances, as previously low proton density in lung tissue and pulmonary and cardiac motion made it hard to get an accurate assessment.Xenoview involves a single 10- to 15-second breath hold during an MRI as the patient wears the chest coil device. The image of the inhaled hyperpolarised xenon 129 gas reveals how deeply air would enter into lung tissue whilst breathing, helping to diagnose and manage patients with serious lung conditions, including chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF).London Stock Exchange-listed Polarean noted there are more than 30 million people in the US with chronic lung diseases, adding that there is a significant unmet need for non-invasive diagnostic technologies like Xenoview which provide regional maps of ventilation in the lungs.The approval is the culmination of a lengthy effort by the North Carolina-based company to get the imaging technology over the regulatory line.It's first marketing application was turned down in October 2021 with an FDA request for more technical and manufacturing information focusing on the xenon hyperpolariser system.Polarean refiled in March 2022, and six months later the FDA requested additional information from the contract manufacturing organisation (CMO) responsible for manufacturing the xenon 129 gas blend used in Xenoview.With approval now in hand, the company intends to focus its commercialisation efforts towards the top 1,000 or so US academic and teaching hospitals providing respiratory medicine services.It estimates that the market equipment alone could be $500 million, backed up by ongoing sales of the contrast agent for diagnostic use, as well as for supporting pharma companies running trials of new therapies for respiratory diseases.https://pharmaphorum.com/news/fda-clears-polareans-lung-disease-diagnostic-xenoview

[pirates4] 10/5/2024 21:11

It's just the beginning.